ArticleOncoimmunology2013
Functional characterization of a STAT3-dependent dendritic cell-derived CD14
Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 35 citations in OpenAlex.
- A new era in melanoma immunotherapy: focus on DCs metabolic reprogramming.Cancer cell international · 2025Review
- Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It.Biomolecules · 2025Review
- Guidelines for preparation and flow cytometry analysis of human nonlymphoid tissue DC.European journal of immunology · 2025Article
- Allogeneic NK cells induce the in vitro activation of monocyte-derived and conventional type-2 dendritic cells and trigger an inflammatory response under cancer-associated conditions.Clinical and experimental immunology · 2024Article
- Allogeneic NK cells induce monocyte-to-dendritic cell conversion, control tumor growth, and trigger a pro-inflammatory shift in patient-derived cultures of primary and metastatic colorectal cancer.Journal for immunotherapy of cancer · 2023Article
- Article
- Dendritic Cell Subsets in Melanoma: Pathophysiology, Clinical Prognosis and Therapeutic Exploitation.Cancers · 2023Review
- Bringing Macrophages to the Frontline against Cancer: Current Immunotherapies Targeting Macrophages.Cells · 2021Review
- Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy.Cancers · 2021Review
- Micro-environmental cross-talk in an organotypic human melanoma-in-skin model directs M2-like monocyte differentiation via IL-10.Cancer immunology, immunotherapy : CII · 2020Article
- Oncolytic adenovirus ORCA-010 increases the type 1 T cell stimulatory capacity of melanoma-conditioned dendritic cells.Clinical and experimental immunology · 2020Article
- The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture.Nature communications · 2020Article
- Primary Resistance to PD-1-Based Immunotherapy-A Study in 319 Patients with Stage IV Melanoma.Cancers · 2020Article
- Thrombomodulin-expressing monocytes are associated with low-risk features in myelodysplastic syndromes and dampen excessive immune activation.Haematologica · 2020Article
- Soluble factors derived from neuroblastoma cell lines suppress dendritic cell differentiation and activation.Cancer science · 2019Article
- Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination.Oncotarget · 2017Article
- Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma.Frontiers in immunology · 2017Review
- Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2016Article
- CD14Oncoimmunology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin (IL)-10 is a major cancer-related immunosuppressive factor, exhibiting a unique ability to hamper the maturation of dendritic cells (DCs). We have previously reported that IL-10 induces the conversion of activated, migratory CD1a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.